Insulet Corporation (PODD) Fair Value & Analysis
Healthcare · US · Market cap $11.0B
Insulet Corporation
PODD · US
Fair value as of: Jul 16, 2026
From 26 valuation models · updated 23 days ago
Fair value updated Jul 16, 2026, revised from $84.09 to $78.48 (−6.7%) since Jun 24, 2026. Share price −13.8% over the past month.
A solid business, but screening 44% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case ($132.51). The favourable scenario is already priced in.
- Solid but not exceptional quality (54/100) and above fair value, neither a clear bargain nor a standout compounder.
- A fairly wide model range ($58.86 to $132.51) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 16, 2026.
How to read this chart
60‑month range $127.77 – $352.82 · fair‑value band $58.86 – $132.51 · the $139.30 price screens above the $78.48 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 16, 2026.
Analysis
Insulet Corporation (PODD) currently trades at $139.30, while our model-based Fair Value estimate is $78.48, implying the stock looks roughly 43.7% overvalued today. We read business quality at 54/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Insulet Corporation generated revenue of $2.9B at a net margin of 10.4%. Revenue grew 33.9% year over year. It earns a return on equity of 23.0%. Net debt stands at $335M. Fundamentals as of Jul 16, 2026
Our scenario range runs from $58.86 (bear case) to $132.51 (bull case); at $139.30, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 61% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -22% fair-value upside, at -44%, PODD screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 26 models by family
Widest divergence: Growth Earnings ($160.89) versus Dividend Discount ($2.46). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 16, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 69 · Market factors (momentum, volatility) 16
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
Full company description
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Insulet Corporation reported revenue of $2.7B in FY2025 versus $1.1B in FY2021, a compound +25.3%/yr. Reported net income was $247M in FY2025, compounding +95.8%/yr from FY2021.
PODD screens 44% overvalued. Compare with Abbott Laboratories, →
Recent news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- ROSEN, A RANKED AND LEADING FIRM, Encourages Insulet Corporation Investors to Secure Counsel Before Important Deadline in Securities Class A
- INSULET CORPORATION INVESTORS WITH LOSSES HAVE UNTIL AUGUST 31, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Dead
- PODD Court Deadline: Insulet Investor Deadline in Securities Fraud Class Action is August 31 – Contact BFA Law if You Lost Money
- PODD SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on Behalf of Insulet Corporation Investors - Contact Kirby McInerney LLP by August 31
Peer Group
Medical Devices · 350 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Devices median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Insider activity: 66/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Devices stocks, each showing price versus our Fair Value estimate (as of Jul 16, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Abbott Laboratories, ABT | $100.68 | $74.79 | -26% |
| Stryker Corporation SYK | $316.44 | $186.28 | -41% |
| Medtronic plc MDT | $83.56 | $65.57 | -22% |
| Boston Scientific Corporation BSX | $43.04 | $38.44 | -11% |
| Edwards Lifesciences Corporation EW | $85.73 | $41.02 | -52% |
| Siemens Healthineers AG SHL | €34.59 | €33.87 | -2% |
| Shenzhen Mindray Bio-Medical Electronics Co 300760 | ¥149.43 | ¥147.63 | -1% |
| Shanghai United Imaging Healthcare Co 688271 | ¥109.00 | ¥43.60 | -60% |
| Demant A/S DEMANT | kr 276.60 | kr 161.17 | -42% |
| Getinge AB GETIB | kr 206.80 | kr 192.14 | -7% |
Compare Insulet Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Insulet Corporation (PODD) overvalued or undervalued?
What is the fair value of PODD?
What is the quality score of PODD?
What is the revenue of Insulet Corporation (PODD)?
What is the net profit margin of PODD?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Insulet Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.